ESBATech initiates Phase IIa uveitis trial
This study is designed to evaluate the safety, tolerability and clinical activity of topically applied ESBA105 in uveitis patients. ESBA105 is a single-chain antibody fragment directed against TNF-alpha,
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an implied equity value of nearly $150m.